Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1126-TCR
- Development stage
- Preclinical
- Lead developer
- Antwerp University Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
WT1126-TCR is an investigational T-cell receptor (TCR) engineered T-cell therapy (TCR-T) designed to target the Wilms' tumor protein 1 (WT1) antigen. Specifically, it is engineered to express a recombinant TCR that recognizes the HLA-A*02:01-restricted WT1126-134 peptide (RMFPNAPYL), which is highly expressed in acute myeloid leukemia (AML) and other hematological malignancies. Developed by researchers at the University Medical Center Utrecht, Memorial Sloan Kettering Cancer Center, and the University of Antwerp, the therapy utilizes CRISPR-Cas9 gene editing to knock out endogenous TCR alpha and beta chains, preventing TCR mispairing and competition, thereby enhancing the expression and functional avidity of the transgenic WT1126-TCR. The therapy is being investigated for the prevention and treatment of relapse in pediatric and adult patients with AML following hematopoietic stem cell transplantation.
- Other names
- WT1126 TCRWT-1126 TCRWT 1126 TCRWT1126-TCR-TWT-1126-TCR-TWT 1126-TCR-TWT1126-specific TCRWT-1126-specific TCRWT 1126-specific TCR
Beyond the preview
Go deeper on WT1126-TCR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1126-TCR.